Amoy Diagnostics Co., Ltd.
SZSE:300685.SZ
19.74 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,038.835 | 842.18 | 917.033 | 728.391 | 578.356 | 439.031 | 330.371 | 252.987 | 176.878 | 106.811 | 74.378 | 38.147 |
| Cost of Revenue
| 215.258 | 147.81 | 143.275 | 94.943 | 55.706 | 39.358 | 25.241 | 23.225 | 12.119 | 6.209 | 5.032 | 3.412 |
| Gross Profit
| 823.577 | 694.37 | 773.759 | 633.447 | 522.65 | 399.673 | 305.131 | 229.762 | 164.759 | 100.602 | 69.346 | 34.735 |
| Gross Profit Ratio
| 0.793 | 0.824 | 0.844 | 0.87 | 0.904 | 0.91 | 0.924 | 0.908 | 0.931 | 0.942 | 0.932 | 0.911 |
| Reseach & Development Expenses
| 177.387 | 174.532 | 156.119 | 115.105 | 93.754 | 78.336 | 50.828 | 49.313 | 33.777 | 20.396 | 12.978 | 0 |
| General & Administrative Expenses
| 41.836 | 42.535 | 54.779 | 87.911 | 47.883 | 10.894 | 9.995 | 6.702 | 18.612 | 6.213 | 19.782 | 13.625 |
| Selling & Marketing Expenses
| 329.494 | 303.779 | 302.914 | 233.562 | 220.272 | 171.902 | 129.767 | 108.366 | 77.177 | 47.745 | 31 | 16.771 |
| SG&A
| 377.735 | 346.314 | 357.693 | 321.474 | 268.156 | 182.796 | 139.762 | 115.068 | 95.789 | 53.959 | 50.782 | 30.396 |
| Other Expenses
| -6.39 | -1.58 | -1.259 | -1.436 | -1.1 | -1.549 | 0.579 | 13.222 | 5.46 | 6.024 | 9.819 | 5.858 |
| Operating Expenses
| 555.123 | 524.251 | 508.899 | 415.038 | 365.741 | 263.244 | 194.525 | 179.938 | 146.671 | 82.059 | 51.598 | 30.88 |
| Operating Income
| 268.454 | 287.663 | 253.238 | 202.145 | 162.45 | 143.925 | 106.354 | 59.949 | 19.31 | 16.904 | 16.64 | 3.711 |
| Operating Income Ratio
| 0.258 | 0.342 | 0.276 | 0.278 | 0.281 | 0.328 | 0.322 | 0.237 | 0.109 | 0.158 | 0.224 | 0.097 |
| Total Other Income Expenses Net
| 39.212 | -1.58 | -1.259 | -1.436 | -1.1 | -1.549 | 0.579 | 13.105 | 5.291 | 6.015 | 9.75 | 5.858 |
| Income Before Tax
| 307.666 | 286.083 | 251.979 | 200.709 | 161.35 | 142.376 | 106.933 | 73.054 | 24.601 | 22.919 | 26.389 | 9.568 |
| Income Before Tax Ratio
| 0.296 | 0.34 | 0.275 | 0.276 | 0.279 | 0.324 | 0.324 | 0.289 | 0.139 | 0.215 | 0.355 | 0.251 |
| Income Tax Expense
| 33.373 | 21.791 | 12.955 | 20.383 | 25.876 | 15.638 | 12.868 | 7.59 | 6.113 | 3.78 | 4.34 | 1.596 |
| Net Income
| 261.484 | 263.743 | 239.574 | 180.326 | 135.474 | 126.738 | 94.066 | 67.034 | 21.085 | 19.139 | 22.05 | 7.973 |
| Net Income Ratio
| 0.252 | 0.313 | 0.261 | 0.248 | 0.234 | 0.289 | 0.285 | 0.265 | 0.119 | 0.179 | 0.296 | 0.209 |
| EPS
| 0.66 | 0.67 | 0.6 | 0.46 | 0.52 | 0.33 | 0.28 | 0.23 | 0.072 | 0 | 0 | 0 |
| EPS Diluted
| 0.66 | 0.67 | 0.6 | 0.45 | 0.52 | 0.33 | 0.28 | 0.23 | 0.072 | 0 | 0 | 0 |
| EBITDA
| 327.616 | 247.129 | 298.192 | 237.665 | 189.235 | 166.007 | 125.344 | 90.832 | 39.59 | 30.706 | 23.031 | 7.532 |
| EBITDA Ratio
| 0.315 | 0.293 | 0.325 | 0.326 | 0.327 | 0.378 | 0.379 | 0.359 | 0.224 | 0.287 | 0.31 | 0.197 |